Kyung-Sun Kang

Dr. Kyung-Sun Kang

Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YKYoon-Jin Kim
Yoon-Jin Kim
SYSae Mi Yoo
Sae Mi Yoo
HPHwan Hee Park
Hwan Hee Park
HLHye Jin Lim
Hye Jin Lim
YKYu-Lee Kim
Yu-Lee Kim
KKKyung-Sun Kang
Kyung-Sun Kang

23 February 2006 in Stem Cells
Verified
Journal Article
Open access
PDF file
SKSung-Whan Kim
Sung-Whan Kim
HHHoon Han
Hoon Han
GCGue-Tae Chae
Gue-Tae Chae
SLSung-Hoon Lee
Sung-Hoon Lee
SBSun Bo
Sun Bo
KKKyung-Sun Kang
Kyung-Sun Kang
Buerger's disease, also known as thromboangiitis obliterans, is a nonatherosclerotic, inflammatory, vasoocclusive disease. It is characterized pathologically as a panangiitis of medium and small blood vessels, including both arteries and adjacent veins, especially the distal extremities (the feet and the hands). There is no curative medication or surgery for this disease. In the present study, we transplanted human leukocyte antigen-matched human umbilical cord blood (UCB)-derived mesenchymal stem cells (MSCs) into four men with Buerger's disease who had already received medical treatment and surgical therapies. After the stem cell transplantation, ischemic rest pain suddenly disappeared from their affected extremities. The necrotic skin lesions were healed within 4 weeks. In the follow-up angiography, digital capillaries were increased in number and size. In addition, vascular resistance in the affected extremities, compared with the preoperative examination, was markedly decreased due to improvement of the peripheral circulation. Because an animal model of Buerger's disease is absent and also to understand human results, we transplanted human UCB-derived MSCs to athymic nude mice with hind limb ischemia by femoral artery ligation. Up to 60% of the hind limbs were salvaged in the femoral artery-ligated animals. By in situ hybridization, the human UCB-derived MSCs were detected in the arterial walls of the ischemic hind limb in the treated group. Therefore, it is suggested that human UCB-derived MSC transplantation may be a new and useful therapeutic armament for Buerger's disease and similar ischemic diseases.

20 September 2002 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
HHHongbo Hu
Hongbo Hu
NANam‐Shik Ahn
Nam‐Shik Ahn
XYXinlin Yang
Xinlin Yang
YLYong‐Soon Lee
Yong‐Soon Lee
KKKyung-Sun Kang
Kyung-Sun Kang
Although the pharmacology and clinical application of water extracts of Ganoderma lucidum have been extensively documented, little is known regarding its alcohol extract. In the present study, the anti‐tumor effect of an alcohol extract of Ganoderma lucidum was investigated using MCF‐7 cells. We found that the alcohol extract of Ganoderma lucidum inhibited cell proliferation in a dose‐ and time‐dependent manner, which might be mediated through up‐regulation of p21/Waf1 and down‐regulation of cyclin D1. Furthermore, this compound can directly induce apoptosis in MCF‐7 cells, which might be mediated through up‐regulation of a pro‐apoptotic Bax protein and not by the immune system. Our findings suggest that there are multiple mechanisms underlying the anti‐tumor effects of Ganoderma lucidum.

1 January 2009 in Cytotherapy
Verified
Journal Article
Closed access
PDF file
BSBo Sun
Bo Sun
KRKyoung-Hwan Roh
Kyoung-Hwan Roh
JPJeong-Ran Park
Jeong-Ran Park
SLSae-Rom Lee
Sae-Rom Lee
SPSang-Bum Park
Sang-Bum Park
KKKyung-Sun Kang
Kyung-Sun Kang
Mesenchymal stromal cells (MSC) have been studied intensively in regenerative medicine. However, their therapeutic potential against tumor formation and cancer metastasis is still unclear. The effects of transplantation of MSCs in early-stage of carcinogenesis, should be evaluated. MSC isolated from human umbilical cord blood (UCB) and adipose tissue (AD) were transplanted in a mouse cancer metastasis model. The effects of MSC on tumor growth and metastasis were analyzed. The effects of transplantation of MSC into the mouse model at very early stage carcinogenesis were also evaluated. Human MSC reduced lung metastasis and inhibited the growth of human breast cancer cells by inducing apoptosis. In addition, transplantation of both UCB and AD MSC into a cancer model with no detectable clinical symptoms did not appear to promote tumor growth or metastasis. We evaluated the effect of MSC derived from human UCB and AD tissue in a tumor model. Our findings may help to elucidate the interaction between cancer cells and MSC, as well as the application of MSC to clinical trials.

24 March 2015 in Stem Cells
Verified
Journal Article
Open access
PDF file
HKHyung-Sik Kim
Hyung-Sik Kim
JYJun-Won Yun
Jun-Won Yun
TSTae-Hoon Shin
Tae-Hoon Shin
SLSung-Hoon Lee
Sung-Hoon Lee
BLByung-Chul Lee
Byung-Chul Lee
KKKyung-Sun Kang
Kyung-Sun Kang
Mesenchymal stem cell (MSC) is a promising tool for the therapy of immune disorders. However, their efficacy and mechanisms in treating allergic skin disorders are less verified. We sought to investigate the therapeutic efficacy of human umbilical cord blood-derived MSCs (hUCB-MSCs) against murine atopic dermatitis (AD) and to explore distinct mechanisms that regulate their efficacy. AD was induced in mice by the topical application of Dermatophagoides farinae. Naïve or activated-hUCB-MSCs were administered to mice, and clinical severity was determined. The subcutaneous administration of nucleotide-binding oligomerization domain 2 (NOD2)-activated hUCB-MSCs exhibited prominent protective effects against AD, and suppressed the infiltration and degranulation of mast cells (MCs). A β-hexosaminidase assay was performed to evaluate the effect of hUCB-MSCs on MC degranulation. NOD2-activated MSCs reduced the MC degranulation via NOD2-cyclooxygenase-2 signaling. In contrast to bone marrow-derived MSCs, hUCB-MSCs exerted a cell-to-cell contact-independent suppressive effect on MC degranulation through the higher production of prostaglandin E2 (PGE2). Additionally, transforming growth factor (TGF)-β1 production from hUCB-MSCs in response to interleukin-4 contributed to the attenuation of MC degranulation by downregulating FcεRI expression in MCs. In conclusion, the subcutaneous application of NOD2-activated hUCB-MSCs can efficiently ameliorate AD, and MSC-derived PGE2 and TGF-β1 are required for the inhibition of MC degranulation. Stem Cells 2015;33:1254–1266

10 May 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASAh-Young So
Ah-Young So
JJJi-Won Jung
Ji-Won Jung
SLSeunghee Lee
Seunghee Lee
HKHyung-Sik Kim
Hyung-Sik Kim
KKKyung-Sun Kang
Kyung-Sun Kang
Epigenetic regulation of gene expression is well known mechanism that regulates cellular senescence of cancer cells. Here we show that inhibition of DNA methyltransferases (DNMTs) with 5-azacytidine (5-AzaC) or with specific small interfering RNA (siRNA) against DNMT1 and 3b induced the cellular senescence of human umbilical cord blood-derived multipotent stem cells (hUCB-MSCs) and increased p16INK4A and p21CIP1/WAF1 expression. DNMT inhibition changed histone marks into the active forms and decreased the methylation of CpG islands in the p16INK4A and p21CIP1/WAF1 promoter regions. Enrichment of EZH2, the key factor that methylates histone H3 lysine 9 and 27 residues, was decreased on the p16INK4A and p21CIP1/WAF1 promoter regions. We found that DNMT inhibition decreased expression levels of Polycomb-group (PcG) proteins and increased expression of microRNAs (miRNAs), which target PcG proteins. Decreased CpG island methylation and increased levels of active histone marks at genomic regions encoding miRNAs were observed after 5-AzaC treatment. Taken together, DNMTs have a critical role in regulating the cellular senescence of hUCB-MSCs through controlling not only the DNA methylation status but also active/inactive histone marks at genomic regions of PcG-targeting miRNAs and p16INK4A and p21CIP1/WAF1 promoter regions.